Improving effects of topical administration of iganidipine, a new calcium channel blocker, on the impaired visual evoked potential after endothelin-1 injection into the vitreous body of rabbits

Current Eye Research

Volumn 20, Issue 2, 2000, Pages 101-108

  Oku, Hidehiro ^a   Sugiyama, Tetsuya ^a   Kojima, Shota ^a   Watanabe, Toshio ^a   Ikeda, Tsunehiko ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Calcium channel blocker; Endothelin 1; Iganidipine; Rabbit; Visual evoked potential

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DRUG VEHICLE; ENDOTHELIN 1; IGANIDIPINE; LIDOCAINE; MYDRIN P; NEW DRUG; PENTOBARBITAL; PHENYLEPHRINE; TROPICAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; EVOKED VISUAL RESPONSE; INTRAOCULAR PRESSURE ABNORMALITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; VITREOUS BODY;

EID: 0033954210     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/0271-3683(200002)2021-DFT101     Document Type: Article

References (36)

1. Kitazawa Y, Shirai H, Go FJ. The effects of Ca-antagonist on visual field in low-tension glaucoma. Graefe's Arch Clin Exp Ophthalmol. 1996;227:408-412.
2. Netland PA, Chaturvedi N, Dreyer EB. Calcium channel blockers in the management of low-tension and openangle glaucoma. Am J Ophthalmol 1993;115:608-613.
3. Sawada A, Kitazawa Y, Yamamoto T, Okabe I, Ichien K. Prevention of visual field defect progression with brovincamine in eyes with normal-tension glaucoma. Ophthalmology. 1996;103:283-288.
4. Higuchi H, Fukuda T, Ukai K, Miyata M. Visual function analysis of diabetic retinopathy using contrast sensitivity analyzer and usefulness of nicardipine hydrochloride [in Japanese]. J Jpn Ophthalmol Society. 1995;99: 914-919.
5. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
6. MacCumber MW, Jampel HD, Snyder SH. Ocular effects of the endothelins. Abundant peptides in the eye. Arch Ophthalmol. 1991;109:705-709.
7. Chakravarthy U, Douglas AJ, Bailie JR, McKibben B, Archer DB. Immunoreactive endothelin distribution in ocular tissues. Invest Ophthalmol Vis Sci. 1994;35:2448-2454.
8. Haefliger IO, Flammer J, Luscher TF. Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest Ophthalmol Vis Sci. 1992;33:2340-2343.
9. Haefliger IO, Meyer P, Flammer J, Luscher TF. The vascular endothelium as a regulator of the ocular circulation: a new concept in ophthalmology? Surv Ophthalmol. 1994;39:123-132.
10. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologica. 1990;33:306-310.
11. Sugiyama T, Moriya S, Oku H, Azuma I. Association of endothelin-1 with normal tension glaucoma: clinical and fundamental studies. Surv Ophthalmol. 1995;39(Suppl 1):S49-56.
12. Kaiser HJ, Flammer J, Wenk M, Luscher TF. Endothelin-1 plasma levels in normal-tension glaucoma: abnormal response to postural changes. Graefe's Arch Clin Exp Ophthalmol. 1995;233:484-488.
13. Cioffi GA, Orgül S, Onda E, Bacon DR, Van-Buskirk EM. An in vivo model of chronic optic nerve ischemia: the dose-dependent effects of endothelin-1 on the optic nerve microvasculature. Curr Eye Res. 1995;14:1147-1153.
14. Orgül S, Cioffi GA, Wilson DJ, Bacon DR, Van-Buskirk EM. An endothelin-1 induced model of optic nerve ischemia in the rabbit. Invest Ophthalmol Vis Sci. 1996; 37:1860-1869.
15. Oku H, Sugiyama T, Kojima S, Watanabe T, Azuma I. Experimental optic cup enlargement caused by endothelin-1-induced chronic optic nerve head ischemia. Surv Ophthalmol. (in press).
16. Hughes A, Wilson ME. Callosal terminations along the boundary between visual areas I and II in the rabbit. Brain Res. 1969;12:19-25.
17. Kawasaki K, Mochizuki K, Yonemura D, Ohnogi J, Okayama Y. Effects of intravitreal injection of sulfobenzylpenicillin on the ERG and VEP. J Jpn Ophthalmol Society. 1989;89:1334-1339.
18. Nyborg NCB, Prieto D, Benedito S, Nielsen PJ. Endothelin-1-induced contraction of bovine retinal small arteries is reversible and abolished by nitrendipine. Invest Ophthalmol Vis Sci. 1991;32:27-31.
19. Sakaue H, Kiryu J, Takeuchi A, Honda Y. Effects of endothelin on retinal blood vessels [in Japanese]. J Jpn Ophthalmol Society. 1991;96:469-472.
20. Yamada S, Kimura R. Pharmacodynamics and phamacokinetics of iganidipine. Cardiovasc Drug Rev. 1996; 14:213-230.
21. Wada K, Nakamura S, Morishita S, Kanda M, Mitsui H, Fukuta F, Shirahase H. Antihypertensive effect of the novel water-soluble calcium antagonist (±)-3-(4-allyl-1-piperazinyl)-2, 2-dimethylpropyl methyl 1,4-dihydro-2, 6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate dihydrochloride in rats. Arzneimittelforschung. 1994; 44(II):1112-1116.
22. Kanda M, Shirahase H, Kurihashi K, Wada K, Nakamura S, Matsui H, Fukuta F. Effect of the novel water-soluble calcium antagonist (±)-3-(4-allyl-1-piperazinyl)-2, 2-dimethylpropyl methyl 1, 4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3, 5-pyridinedicarboxylate dihydrochloride on the responses of isolated canine arteries. Arzneimittelforschung. 1995;45:831-835.
23. Hirata Y, Yoshimi H, Takata S, Watanabe TX, Kumagai S, Nakajima K, Sakakibara S. Cellular mechanism of action by novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. Biochem Biophys Res commun. 1988;154:868-875.
24. Goto K, Kasuya Y, Matsuki N, Takuwa Y, Kurihara H, Ishikawa T, Kimura S, Yanagisawa M, Masaki T. Endothelin activates the dihydropyridine-sensitive, voltage-dependent Ca2+ channel in vascular smooth muscle. Proc Natl Acad Sci U.S.A. 1989;86:3915-3918.
25. Van Renterghem C, Vigne P, Barhanin J, Schmid AA, Frelin C, Lazdunski M. Molecular mechanism of action of vasoconstrictor peptide endothelin. Biophys.Res. Commun. 1988;157:977-985.
26. Meyer P, Lang MG, Flammer J, Luscher TF. Effects of calcium channel blockers on the response to endothelin-1, bradykinin and sodium nitroprusside in porcine ciliary arteries. Exp Eye Res. 1995;60:505-510.
27. Oku H, Sugiyama T, Moriya S, Hamada J, Azuma I. Effects of intravitreal injection of endothelin on the visual system [in Japanese]. J Jpn Ophthalmol Society. 1993;97:467-473.
28. Sato T, Takei K, Nonoyama T, Miyauchi T, Goto K, Hommura S. Endothelin-1-induced vasoconstriction in retinal blood vessels in the rabbit [in Japanese]. J Jpn Ophthalmol Society. 1993;97:683-689.
29. Granstam E, Wang L, Bill A. Ocular effects of endothelin-1 in the cat. Curr Eye Res. 1992;11:325-332.
30. Sugiyama T, Oku H., Moriya S, Shimizu K, Hamada J, Azuma I. Effect of endothelin-1 on ocular circulation. [in Japanese] J Jpn Ophthalmol Society. 1993;97:678-682.
31. Hara H, Yokota K, Shimazawa M, Sakamoto T. Effects of KB-2796, a new diphenylpiperazine Ca2+ antagonist, on glutamate neurotoxicity in rat hyppocampal primary cell cultures. Jpn J Phamacol. 1993;61:361-365.
32. Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH. Mechanism of nitric-oxide mediated neurotoxicity in primary brain. J Neuroscience. 1993;13:2651-2661.
33. Kashii S, Mandai M, Kikuchi M, Honda Y, Tamura Y, Kaneda K, Akaike A. Dual actions of nitric oxide in N-methyl-D-aspartate receptor-mediated neurotoxicity in cultured retinal neurons. Brain Res. 1996;711:93-101.
34. Adachi K, Fujita Y, Morizane C, Akaike A, Ueda M, Satoh M, Masai H, Kashii S, Honda Y. Inhibition of NMDA receptors and nitric oxide synthase reduces ischemie injury of the retina. Eur J Pharmacol. 1998;350: 53-57.
35. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114:299-305.
36. Watanabe N, Ogawa T, Waki M, Sugiyama T, Oku H, Ota M, Azuma I. Effects of iganidipine hydrochloride, calcium antagonist, ophthalmic solution on impairment of both blood flow of optic nerve head and visual function induced by endothelin-1 in rabbits. Exp Eye Res. 1998;67(Suppl 1):S239. Abstract.